|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0144576,
umls-concept:C0201734,
umls-concept:C0205195,
umls-concept:C0205314,
umls-concept:C0205390,
umls-concept:C0242640,
umls-concept:C0290741,
umls-concept:C0376622,
umls-concept:C0450442,
umls-concept:C0679622,
umls-concept:C0754576,
umls-concept:C0919458,
umls-concept:C1514559,
umls-concept:C1537665,
umls-concept:C1555029,
umls-concept:C1704873,
umls-concept:C1704939,
umls-concept:C1823242,
umls-concept:C1825410
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1998-9-29
|
|
pubmed:abstractText |
To evaluate the feasibility of administering biricodar (VX-710; Incel, Vertex Pharmaceuticals Inc, Cambridge, MA), an agent that modulates multidrug resistance (MDR) conferred by overexpression of both the multidrug resistance gene product (MDR1) P-glycoprotein and the MDR-associated protein (MRP) in vitro, in combination with paclitaxel. The study also sought to determine the maximum-tolerated dose (MTD) of paclitaxel that could be administered with biologically relevant concentrations of VX-710 and characterize the toxicologic and pharmacologic profiles of the VX-710/ paclitaxel regimen.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AylesworthCC,
pubmed-author:CampbellEE,
pubmed-author:ChaturvediPP,
pubmed-author:DrenglerRR,
pubmed-author:EckhardtS GSG,
pubmed-author:HammondLL,
pubmed-author:HardingM WMW,
pubmed-author:KraynakMM,
pubmed-author:RowinskyE KEK,
pubmed-author:SmithLL,
pubmed-author:StephensonJJJr,
pubmed-author:VillalonaMM,
pubmed-author:Von HoffD DDD,
pubmed-author:WangY MYM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2964-76
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:9738565-ATP-Binding Cassette Transporters,
pubmed-meshheading:9738565-Adult,
pubmed-meshheading:9738565-Aged,
pubmed-meshheading:9738565-Aged, 80 and over,
pubmed-meshheading:9738565-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9738565-Dose-Response Relationship, Drug,
pubmed-meshheading:9738565-Drug Administration Schedule,
pubmed-meshheading:9738565-Drug Interactions,
pubmed-meshheading:9738565-Drug Resistance, Multiple,
pubmed-meshheading:9738565-Female,
pubmed-meshheading:9738565-Humans,
pubmed-meshheading:9738565-Immunosuppressive Agents,
pubmed-meshheading:9738565-Infusions, Intravenous,
pubmed-meshheading:9738565-Male,
pubmed-meshheading:9738565-Middle Aged,
pubmed-meshheading:9738565-Multidrug Resistance-Associated Proteins,
pubmed-meshheading:9738565-Neoplasms,
pubmed-meshheading:9738565-P-Glycoprotein,
pubmed-meshheading:9738565-Paclitaxel,
pubmed-meshheading:9738565-Piperidines,
pubmed-meshheading:9738565-Pyridines
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
|
|
pubmed:affiliation |
Institute for Drug Development, University of Texas Health Science Center, San Antonio 78229, USA. erowinsk@saci.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
